cetuximab

You have access
Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients
IGOR KISS, JITKA MLCOCHOVA, ZBYNEK BORTLICEK, ALEXANDR POPRACH, JIRI DRABEK, PETRA VYCHYTILOVA-FALTEJSKOVA, MAREK SVOBODA, TOMAS BUCHLER, STANISLAV BATKO, ALES RYSKA, MARIAN HAJDUCH and ONDREJ SLABY

Anticancer Research September 2016, 36 (9) 4955-4959;
You have access
The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment
LUBOS HOLUBEC, JIRI POLIVKA, MARTIN SAFANDA, MICHAL KARAS and VACLAV LISKA

Anticancer Research September 2016, 36 (9) 4421-4426;
You have access
Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer
ANNE PLOQUIN, FARID ZERIMECH, FABIENNE ESCANDE, ANTOINE ADENIS, CLAIRE GIRAUD, LAURENT GASNAULT, VINCENT BOURGEOIS, CHRISTOPHE DESAUW and MOHAMED HEBBAR

Anticancer Research August 2016, 36 (8) 4233-4236;
You have access
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
TOSHIFUMI YAMAGUCHI, SATORU IWASA, KENGO NAGASHIMA, NOBUAKI IKEZAWA, TETSUYA HAMAGUCHI, HIROKAZU SHOJI, YOSHITAKA HONMA, ATSUO TAKASHIMA, NATSUKO OKITA, KEN KATO, YASUHIDE YAMADA and YASUHIRO SHIMADA

Anticancer Research July 2016, 36 (7) 3531-3536;
You have access
Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer
MASAICHI OGAWA, TADASHI ANAN, TOSHIAKI SUZUKI, MASAHISA OKUMA, KOHEI ICHIHARA, TAKUO HASEGAWA, KAZUHIKO YOSHIDA and KATSUHIKO YANAGA

Anticancer Research May 2016, 36 (5) 2505-2511;
You have access
Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores
HOWARD W. BRUCKNER, AZRIEL HIRSCHFELD and MYRON SCHWARTZ

Anticancer Research January 2016, 36 (1) 399-402;
You have access
Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion
MINH HIEN PHAM, LAURE DELESTRE, AMELIE DEWITTE, NICOLE WATTEZ, FREDERIC LEPRETRE and AMELIE LANSIAUX

Anticancer Research November 2015, 35 (11) 5983-5991;
You have access
Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
YI-HSIN LIANG, YU-LIN LIN, JAU-YU LIAU, JIA-HUEI TSAI, JIN-TUNG LIANG, BEEN-REN LIN, JI-SHIANG HUNG, LI-HUI TSENG, LIANG-IN LIN, YIH-LEONG CHANG, ANN-LII CHENG and KUN-HUEI YEH

Anticancer Research July 2015, 35 (7) 4207-4214;
You have access
Circulating Hepatocyte Growth Factor Is Correlated with Resistance to Cetuximab in Metastatic Colorectal Cancer
KIMIO YONESAKA, TAROH SATOH, SHINYA UEDA, TAKESHI YOSHIDA, MASAYUKI TAKEDA, TOSHIO SHIMIZU, ISAMU OKAMOTO, KAZUTO NISHIO, TAKAO TAMURA and KAZUHIKO NAKAGAWA

Anticancer Research March 2015, 35 (3) 1683-1689;
You have access
Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advanced Rectal Cancer – A Phase II Clinical Trial
WOLFGANG EISTERER, ALEXANDER DE VRIES, DIETMAR ÖFNER, HANS RABL, RENATE KOPLMÜLLER, RICHARD GREIL, JÖERG TSCHMELITSCH, RAINER SCHMID, KARIN KAPP, PETER LUKAS, FELIX SEDLMAYER, GERALD HÖFLER, MICHAEL GNANT, JOSEF THALER and on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Anticancer Research November 2014, 34 (11) 6767-6773;

Main menu

User menu

Search

cetuximab

Pages